Cancer is a major chronic disease, which can be managed and treated by chemotherapy, radiation therapy, immunotherapy, hormone therapy, stem cell transplant, targeted therapy, and other therapies. Cancer can be treated by using one therapy or by using combination of therapies based on the stage, type of cancer, and other factors. Chemotherapy is the type of treatment, where the drugs are used to stop or slow the growth of cancer cells. Chemotherapy-induced thrombocytopenia is a serious complication in the chemotherapy-treated patients. This report focus on Chemotherapy-induced Thrombocytopenia Therapeutics market.
This report contains market size and forecasts of Chemotherapy-induced Thrombocytopenia Therapeutics in Global, including the following market information:
Global Chemotherapy-induced Thrombocytopenia Therapeutics Market Revenue, 2017-2022, 2023-2028, ($ millions)
Global top five companies in 2021 (%)
The global Chemotherapy-induced Thrombocytopenia Therapeutics market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period.
The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
Thrombopoietin Receptor Agonists Segment to Reach $ Million by 2028, with a % CAGR in next six years.
The global key manufacturers of Chemotherapy-induced Thrombocytopenia Therapeutics include Amgen Inc., Novartis AG, Teva Pharmaceutical Industries Ltd, Mylan N.V., Pfizer Inc, Janssen Global Services, LLC, Partner Therapeutics, Inc, Mission Pharmacal Company and Myelo Therapeutics GmbH, etc. In 2021, the global top five players have a share approximately % in terms of revenue.
MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Chemotherapy-induced Thrombocytopenia Therapeutics companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Chemotherapy-induced Thrombocytopenia Therapeutics Market, by Type, 2017-2022, 2023-2028 ($ millions)
Global Chemotherapy-induced Thrombocytopenia Therapeutics Market Segment Percentages, by Type, 2021 (%)
Thrombopoietin Receptor Agonists
Thrombopoietic Agents
Others
Global Chemotherapy-induced Thrombocytopenia Therapeutics Market, by Application, 2017-2022, 2023-2028 ($ millions)
Global Chemotherapy-induced Thrombocytopenia Therapeutics Market Segment Percentages, by Application, 2021 (%)
Hospitals Pharmacies
Retail Pharmacies
Online Pharmacies
Global Chemotherapy-induced Thrombocytopenia Therapeutics Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions)
Global Chemotherapy-induced Thrombocytopenia Therapeutics Market Segment Percentages, By Region and Country, 2021 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Chemotherapy-induced Thrombocytopenia Therapeutics revenues in global market, 2017-2022 (estimated), ($ millions)
Key companies Chemotherapy-induced Thrombocytopenia Therapeutics revenues share in global market, 2021 (%)
Further, the report presents profiles of competitors in the market, key players include:
Amgen Inc.
Novartis AG
Teva Pharmaceutical Industries Ltd
Mylan N.V.
Pfizer Inc
Janssen Global Services, LLC
Partner Therapeutics, Inc
Mission Pharmacal Company
Myelo Therapeutics GmbH
Jiangsu HengRui Medicine Co., Ltd
Dova Pharmaceuticals, Inc